STUDY PROTOCOL

Trial protocol of an open label pilot study of lisdexamfetamine for the treatment of acute methamphetamine withdrawal

Liam S. Acheson1,2,3,*, Nadine Ezard2,3,4, Nicholas Lintzeris4,5,6, Adrian Dunlop4,7,8, Jonathan Brett9,10, Craig Rodgers2, Anthony Gill5, Michael Christmass11,12, Rebecca McKetin1, Michael Farrell1, Steve Shoptaw13, Krista J. Siefried1,2,3

1 The National Drug and Alcohol Research Centre (NDARC), the University of New South Wales, Sydney, Australia, 2 Alcohol and Drug Service, St Vincent’s Hospital Sydney, Sydney, Australia, 3 The National Centre for Clinical Research on Emerging Drugs (NCCRED), c/o the University of New South Wales, Sydney, Australia, 4 New South Wales Drug and Alcohol Clinical Research and Improvement Network (DACRIN), Sydney, Australia, 5 The Langton Centre, South East Sydney Local Health District, Sydney, Australia, 6 Discipline of Addiction Medicine, the University of Sydney, Sydney, Australia, 7 Drug and Alcohol Clinical Services, Hunter New England Local Health District, Newcastle, Australia, 8 School of Medicine and Public Health, the University of Newcastle, Newcastle, Australia, 9 Clinical Pharmacology and Toxicology, St Vincent’s Hospital Sydney, Sydney, Australia, 10 St. Vincent’s Clinical School, the University of New South Wales, Sydney, Australia, 11 Next Step Drug and Alcohol Services, Perth, Australia, 12 National Drug Research Institute, Curtin University, Perth, Australia, 13 Department of Family Medicine, The University of California Los Angeles, Los Angeles, California, United States of America

* liam.acheson@svha.org.au

Abstract

Introduction

Methamphetamine (MA) use disorder is an important public health concern. MA withdrawal is often the first step in ceasing or reducing use. There are no evidence-based withdrawal treatments, and no medication is approved for the treatment of MA withdrawal. Lisdexamfetamine (LDX) dimesilate, used in the treatment of attention deficit hyperactivity disorder and binge eating disorder has the potential as an agonist therapy to ameliorate withdrawal symptoms, and improve outcomes for patients.

Methods

A single arm, open-label pilot study to test the safety and feasibility of LDX for the treatment of MA withdrawal. Participants will be inpatients in a drug and alcohol withdrawal unit, and will receive a tapering dose of LDX over five days: 250mg LDX on Day 1, reducing by 50mg per day to 50mg on Day 5. Optional inpatient Days 6 and 7 will allow for participants to transition to ongoing treatment. Participants will be followed-up on Days 14, 21 and 28. All participants will also receive standard inpatient withdrawal care. The primary outcomes are safety (measured by adverse events, changes in vital signs, changes in suicidality and psychosis) and feasibility (the time taken to enrol the sample, proportion of screen / pre-screen failures). Secondary outcomes are acceptability (treatment satisfaction questionnaire, medication adherence, concomitant medications, qualitative interviews), retention to protocol (proportion retained to primary and secondary endpoints), changes in withdrawal symptoms.
Introduction

An estimated 29 million people, or 0.7% of the world’s population aged between 15–64 years old, consumed amphetamine or methamphetamine (MA) in 2017 (hereafter referred to collectively as MA to reflect the most recent data on the context of the Australian market [1, 2]). The use of MA has been associated with depression and anxiety, psychosis, suicidal behaviour, cardiovascular, respiratory and dermatological conditions, blood borne virus transmission, non-fatal injury as well as overdose and death [3–6]. The global, age-standardised rate of MA/amphetamine dependence is estimated to be 96 people per 100,000 [7].

Cessation of MA use following frequent and prolonged use can result in a characteristic withdrawal syndrome, which emerges within hours to days after ceasing or reducing use [8]. This acute withdrawal syndrome is reported to last around 7–10 days and has been characterised by dysphoria, fatigue, sleep disturbances, vivid dreams, increased appetite, and psychomotor agitation or retardation, with symptoms peaking within the first 7 days [8–11]. Successful withdrawal can facilitate engagement with, and a transition to, ongoing treatment (e.g., residential rehabilitation, counselling), resulting in improved health and welfare [12, 13], and early abstinence of at least two weeks is a predictor of longer-term treatment success [14].

There are no evidence-based pharmacotherapies for the treatment of MA withdrawal [10]. Standard care generally involves management of MA withdrawal symptoms (e.g., benzodiazepines to manage anxiety and agitation) despite limited evidence of effectiveness in improving withdrawal outcomes [15]. Neurobiological models of MA withdrawal suggest that acute withdrawal symptoms (e.g. intense cravings, irritability and poor concentration) may result from dopaminergic dysfunction related to chronic exposure to high dose amphetamines [16, 17]. These changes have been correlated with mood and behavioural disturbances seen in people with chronic MA use [18]. At least partial recovery in dopamine transporter function occurs over time, however, this can take months [19]. In contrast, rodent models show the neurobiological changes that occur in withdrawal are potentially immediately reversible with administration of a stimulant [20]. Agonist therapies have been effective in the treatment of withdrawal for other substances (for example buprenorphine for opioid withdrawal [21]), and agonist-like therapies for MA dependence have shown promise in the past, particularly in their effects on craving [22].

A potential candidate drug to treat MA withdrawal is lisdexamfetamine. Lisdexamfetamine (LDX) is a pharmacologically inactive pro-drug of dexamphetamine, a central nervous stimulant which increases extracellular dopamine [23]. LDX has regulatory approval in Australia for the indications for Attention-Deficit / Hyperactivity Disorder (ADHD) and Binge Eating Disorder at doses up to 70 mg per day [24]. LDX is absorbed after oral administration and hydrolysed to inactive metabolites and active dexamphetamine by red blood cells [25]. This results (Amphetamine Withdrawal Questionnaire) and craving for MA (visual analogue scale), and sleep outcomes (continuous actigraphy and daily sleep diary).

Discussion

This is the first study to assess lisdexamfetamine for the treatment of acute MA withdrawal. If safe and feasible results will go on informing the development of multi-centre randomised controlled trials to determine the efficacy of the intervention.
in a slower onset of action/effect and lower peak dopamine concentration compared with immediate release dexamphetamine [26, 27], enabling once daily dosing.

LDX doses of up to 250mg per day have been found to be safe and tolerable in both stimulant-naïve people and a pilot study of people who use MA [23, 28, 29]. A tapering dose regimen is proposed in this protocol to allow for maximum potential attenuation of early withdrawal by providing reducing stimulant exposure through the first five days, when withdrawal symptoms are at their most severe and ensure no residual withdrawal from LDX upon ceasing treatment due to the tapering dose. As the ineffective treatment of MA withdrawal symptoms may lead to higher rates of relapse to use [30, 31], the ability for LDX as a prodrug of dexamphetamine to ameliorate withdrawal symptoms and craving for MA has the potential to improve treatment outcomes during acute withdrawal [32].

This report is a protocol for an open-label, single-arm pilot clinical trial. The protocol was developed in conjunction with SPIRIT guidelines and adheres to the Australian National Statement on Ethical Conduct in Human Research, and Good Clinical Practice guidelines [33–35].

Objectives
This study aims to assess a five-day tapering-dose regimen of LDX for the management of acute MA withdrawal in an inpatient withdrawal setting. We hypothesise that a tapering dose of LDX will be safe and feasible to deliver during inpatient withdrawal from MA.

The primary objective is to determine the safety and feasibility of a 250mg tapering dose of LDX over five days of inpatient treatment. Secondary objectives are: (i) to describe the acceptability of the treatment regimen to participants; (ii) to describe participant retention to the protocol; (iii) to describe changes in withdrawal severity, and (iv) MA craving during and after the treatment regimen; and (v) to describe the sleep wake cycle of people with acute MA withdrawal receiving a five-day tapering dose of LDX.

Materials and methods
Trial design
This study is an open-label, single-arm, pilot clinical trial of a five-day tapering dose regimen of LDX for acute MA withdrawal. Participants are admitted to an inpatient withdrawal unit for up to seven days (five days of medication and two additional optional days for transition to ongoing treatment [e.g. residential rehabilitation, counselling]) and are followed up via telephone or in person once a week until Day 28 (three weeks post discharge).

Sample size
As this is a pilot study, it is not powered to detect differences in treatment efficacy. This study will therefore seek to enrol 15 participants, conventional for studies of this nature [36, 37]. Findings will inform planning for a large-scale RCT of LDX for treatment of MA withdrawal.

Study setting
This study is conducted at a single site inpatient alcohol and other drug withdrawal unit in Sydney, New South Wales, Australia.

Eligibility criteria
Inclusion criteria are adults over the age of 18 years who: are presenting to inpatient drug treatment services seeking treatment for MA withdrawal; have methamphetamine use disorder (MAUD) as determined by an Addiction Medicine specialist according to the Diagnostic and
Table 1. Eligibility criteria.

| Inclusion Criteria | Exclusion Criteria |
|--------------------|-------------------|
| • Adult over the age of 18 years | • Women who are: lactating; pregnant; or of childbearing potential and not willing to avoid becoming pregnant during the study |
| • Presenting to inpatient drug treatment services seeking treatment for acute MA withdrawal (e.g. self-presenting to the centralised intake line, presented to the Emergency Department, presented to the Alcohol and Drug Service etc.) | • Expected concurrent withdrawal from alcohol, opioids, benzodiazepines, gamma-hydroxybutyrate or other gabapentinoids |
| • Methamphetamine Use Disorder as determined by an addiction medicine specialist according to the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) criteria | • Known contraindication(s) to lisdexamfetamine (as per product information [24]) including: |
| • Last MA use within 72 hours of planned first study drug dose | • Advanced arteriosclerosis |
| • Positive urine drug screen for methamphetamines | • Symptomatic cardiovascular disease including cardiac arrhythmia, ischaemic heart disease |
| • Willing and able to provide written informed consent and willing to participate in and comply with the study protocol | • Moderate to severe hypertension |
| | • Hyperthyroidism |
| | • Known hypersensitivity or idiosyncratic reaction to sympathomimetic amines or any of the excipients |
| | • Glaucoma |
| | • Agitated states such as severe anxiety, tension and agitation |
| | • During or within 14 days following the administration of monoamine oxidase inhibitors (hypertensive crises may result) |
| | • Pheochromocytoma |
| | • Tic, Tourette’s syndrome |
| | • Patients who currently exhibit severe depression, anorexia nervosa, psychotic symptoms or suicidal tendency |
| | • Significant medical or psychiatric condition which, in the opinion of a study medical officer, renders a patient unsuitable for the study |
| | • Involuntary patient status |

Statistical Manual of Mental Disorders, 5th Edition (DSM-5) Criteria [11]; report last use of MA within 72 hours of the planned first study drug dose; have a positive urine drug screen for MA on admission, and; are willing and able to provide written informed consent and comply with the study protocol.

Exclusion criteria are: participants who are lactating, pregnant or of childbearing potential and not willing to avoid becoming pregnant during the study; expected concurrent withdrawal from alcohol, opioids, benzodiazepines, gamma-hydroxybutyrate or other gabapentinoids; known contraindication to LDX (as per the product label [24]); a medical or psychiatric comorbidity which in the opinion of a study medical officer renders a patient unsuitable for the study; or, involuntary patients. Full criteria are described in Table 1.

Potential participants are pre-screened by telephone or in person by a researcher prior to admission. This process facilitates orientation to the study, gauges interest, and assesses potential eligibility to participate. Individuals considered potentially eligible are invited to a formal eligibility assessment by a specialist in Addiction Medicine. The assessment schedule, including eligibility assessments, is outlined in Fig 1.

**Intervention**

Participants receive a tapering dose of oral lisdexamfetamine dimesilate in 50mg capsules, beginning with 250 mg once daily (OD) on Day 1, and reduced by 50 mg per day, to 50 mg OD on Day 5 (Table 2).

LDX at a dose of 250 mg is equivalent to approximately 74 mg of dexamphetamine [38], and similar doses of sustained release dexamphetamine (60-110mg) have previously been
| TIMEPOINT (DAYS) | Inpatient period | Follow up |
|-----------------|------------------|-----------|
| **ENROLLMENT:** |                  |           |
| Eligibility screen | X                |           |
| Informed consent  | X                |           |
| Urine Drug Screen - Obstetrics for MAP  | X             |           |
| **INTERVENTIONS:** |                  |           |
| Lisdexamfetamine dimesylate | X X X X |           |
| **ASSESSMENTS:** |                  |           |
| **BASELINE VARIABLES** |          |           |
| Demographics (including lifetime and recent substance use: SSDP) | X | |
| Standard of care pathlogy (FBC, UECF, LFT, HCG) | X | |
| ADHD screening – WURSP | X | |
| Quality of Life – PWP | X X X | |
| Social Support – ESSF | X | |
| Urine drug screen – urinalysis | X | |
| **PRIMARY OUTCOME VARIABLES** |          |           |
| Adverse events | X X X X X X X | |
| Medical assessment (current SUD, prior treatment, medical and psychiatric history, concomitant medication, comorbidities) | X X X X X X X | |
| Medical review (safety): BP, HR, Temperature, SpO2, Sp02 (Once at screening; SSDP days 1-7 as per standard of care) | X X X X X X X | |
| Psychosis – BPRS | X | X | X | |
| Suicidality – C-ESSF | X | X | X | |
| 12-lead electrocardiogram | X | |
| **SECONDARY OUTCOME VARIABLES** |          |           |
| Concomitant medication record in the prior 24 hours (Days 1-7) or prior 7 days (Days 14, 21, 28) | X X X X X X X X X X | |
| Withdrawal – AWSF | X X X X X X X | |
| Craving – VAS | X X X X X X X | |
| Substance use – TLFB | X | X X | X | |
| Substance use in last 24 hours | X X X X X X | |
| Treatment satisfaction – TSMQ-P | X X X | |
| Sleep diary – CSSP modified | X X X X X | |
| Objective sleep measure – actigraphy | X X X X X | |
| Dependence – SDS | X | X | X | |
| Qualitative interview | | |
| Record of ongoing engagement in care (i.e., counselling) | X X X | |
| Participant reimbursement | X X X X X | |

Fig 1. Schedule of enrolment, interventions, and assessments.

https://doi.org/10.1371/journal.pone.0275371.g001
demonstrated to decrease MA withdrawal severity and cravings, and increase retention in care [39, 40].

**Data collection**

**Outcomes.** *Primary outcomes.* Safety is assessed by Adverse Events (AEs) and vital statistics recorded during each study visit. AEs will be analysed and reported for seriousness, severity, causality, relatedness, and expectedness [41]. Vital signs (heart rate, blood pressure, temperature, oxygen saturation and respiratory rate) are recorded four times daily during the inpatient period. Safety is further assessed through differences in symptoms of psychosis and hostility obtained using the psychosis and hostility items of the Brief Psychiatric Rating Scale (BPRS) [42, 43], and suicidality measured by the Columbia Suicide Severity Rating Scale (C-SSRS) at Days 1 and 5 [44]. Feasibility is measured through the proportion of screen and pre-screen failures and time taken to enrol sample.

**Secondary outcomes.** Medication acceptability is measured by the Treatment Satisfaction Questionnaire for Medications II (TSQM-II) [45], medication adherence (proportion of prescribed doses taken and reasons for missing doses), proportion and type of adjuvant symptomatic medication required, and qualitative interviews. Retention is assessed by the proportion of participants retained in the study until Days 5, 7, 14, 21 and 28. Changes in subjective withdrawal severity are measured at each time point using the Amphetamine Withdrawal Questionnaire (AWQ) [46] through to Day 28. Changes in craving for MA during the inpatient period are assessed using a 100mm Visual Analogue Scale (VAS) [47]. Participant sleep is objectively monitored through continuous actigraphy (Philips Actiwatch 2) and subjective sleep quality is measured with a modified Consensus Sleep Diary (CSD) [48].

To describe the sample additional baseline assessments include: the Wender-Utah rating scale (WURS), to screen for co-existing ADHD [49]; and severity of dependence assessed with the Severity of Dependence Scale (SDS) [50]. Quality of life and level of social support is measured using the Personal Wellbeing Index (PWI) and ENRICHD Social Support Inventory (ESSI), respectively [51, 52].

**Procedure**

**Day 0 (screening and eligibility).** When a potential participant is admitted to the inpatient withdrawal management unit, a researcher provides an overview of the study, reviews the participant information sheet with the patient, and answers questions as needed. Patients who are interested in participating in the study are asked to provide written informed consent. The day of admission is defined as Day 0 of the study, and after informed consent is provided participants are screened for eligibility by an addiction medicine specialist signed on to the study as an investigator. If eligible, participants are formally enrolled in the trial and a medical screening and assessment is undertaken. Baseline data including confirmation of recent MA use through a urine drug screen is collected. Usual inpatient withdrawal care (including symptomatic management and psychosocial support) is provided. Concomitant psychosocial

| Study day | Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 |
|-----------|-------|-------|-------|-------|-------|-------|-------|
| Lisdexamfetamine | 250 mg OD | 200 mg OD | 150 mg OD | 100 mg OD | 50 mg OD | - | - |

* OD, daily; dosing should be within +/- 1 hour of scheduled dosing time

https://doi.org/10.1371/journal.pone.0275371.t002
therapy and AEs are recorded. Protocolised adjuvant symptomatic treatment (diazepam for anxiety (maximum 10mg four times daily [QID]) and olanzapine for psychosis (maximum 5mg three times daily [TDS])), as per standard of care are available alongside the experimental treatment as per standard of care in accordance with the protocol.

**Days 1–5 (inpatient period, active medication).** Day 1 is defined as the first morning of admission, to allow for consistent morning dosing for LDX. Participants are assessed daily for safety, AEs, concomitant medication, and concomitant psychosocial therapies. Daily measures of treatment satisfaction, withdrawal severity, cravings for MA, and quality and duration of sleep are assessed.

Participants are invited to participate in a qualitative interview to examine their experiences of participating in the clinical trial to ensure any subsequent trials will include participant perspectives. Interviews are one-on-one, semi-structured, and approximately 30 minutes in duration. They are conducted by study staff trained in qualitative interviewing. One interview will take place between Days 3 and 7. Interviews are conducted in a private room, and electronically recorded and transcribed.

**Days 6–7 (inpatient period, no medication).** Days 6–7 are optional for ongoing inpatient care and monitoring. Adjuvant medication, wraparound withdrawal services and discharge planning continue to be offered as usual. Participants will be assessed daily for AEs, concomitant medications, and concomitant psychosocial therapies.

Admission may extend beyond Day 7 if clinically indicated, independent of the study.

LDX is not available after Day 5. Ongoing standard treatment is individualised in collaboration with external treating clinicians (i.e., outpatient stimulant treatment programs, residential rehabilitation, etc.). Treatment access and engagement following the inpatient withdrawal period is recorded through to Day 28.

**Days 14, 21 and 28 (follow-up).** Participants receive telephone and short message service (SMS) follow-up from a researcher on Days 14, 21 and 28. Safety, concomitant medication and psychosocial therapy, questionnaire completion and ongoing care will be recorded.

All AEs will be followed-up to resolution or until Day 28, whichever is the shorter, regardless of relatedness to study drug.

Participants are reimbursed with supermarket vouchers in line with standard practice [53], at Baseline ($20) and Days 5 ($30), 7($30) 14 ($30), 21 ($30) and 28 ($30) [53]. Total possible remuneration is $170.

**Participant study discontinuation.** Participants who wish to discontinue protocol treatment are offered the opportunity to continue to participate in all remaining research assessments. For those participants who revoke their consent to participate in the study, no further data are collected.

**Study withdrawal criteria.** Consistent with the safety protocols that are standard care at the enrolling site, review by an Addiction Medicine specialist (signed onto the study protocol) will occur where a participant records a single episode of systolic blood pressure >180mmHg or <100mmHg, a resting heart rate >120 beats per minute (bpm) or <50 bpm, or requires >40mg of diazepam over a 24-hour period to manage symptoms. These events are considered AEs. Any AE that is determined to be potentially treatment related and considered a risk to participant safety by a study doctor will result in withdrawal of the participant from the trial for safety concerns.

**Statistical methods**

The adverse event verbatim descriptions will be classified into standardized medical terminology using the Medical Dictionary for Regulatory Activities (MedDRA) version 19.1. AEs will
be coded to primary System Organ Class (SOC) and preferred term (PT) using MedDRA. Descriptive statistics will be used to analyse all AEs by causality and relatedness. Changes in vital signs will be described using medians and interquartile ranges. The proportion of screen failures and participants who commenced study drug; proportion who achieve each dose; and, proportion who are retained in the study or revoke consent will be analysed. Secondary outcomes measure: changes in medication tolerability; proportion of participants who reached primary and secondary end points; MA withdrawal and craving severity; and, quality and duration of sleep. These will be tested for statistical significance using Wilcoxon rank-sum test for non-parametric data. All tests of significance will be conducted at a two-sided alpha level of 0.05. As this is an exploratory study we will: (i) conduct analyses of observed data only; (ii) conduct sensitivity analyses which account for missing data by imputation; and, (iii) report missing data and limitations.

**Data statement**

Study data are collected and managed using Research Electronic Data Capture (REDCap) [54, 55]. The REDCap database is hosted at St. Vincent’s Hospital, Sydney. REDCap is a secure, web-based application designed to support data capture for research studies. All data will be stored on a secure server for 15 years in a de-identified format and only researchers directly involved in the collection or analysis of data will have access to the data. At trial completion the de-identified database will be made available to researchers by reasonable request only, due to the small sample size of this pilot study, to ensure the preservation of participant anonymity.

**Data safety monitoring board (DSMB) and safety review plan**

A Data Safety Monitoring Board (DSMB) will convene for the purposes of ensuring participant safety for the duration of the study. The DSMB will review the accumulated data for participant safety and AEs. The DSMB will meet following completion of the first participant, and quarterly thereafter. The DSMB comprises an Addiction Medicine specialist with expertise in the treatment of substance use disorders, a Senior Clinical Trialist with experience in the design and conduct of clinical trials, and a Biostatistician with experience in quantitative data analysis; all otherwise not involved in the study. The DSMB will make recommendations related to the continuation, modification or termination of the project as per the DSMB charter in line with NHMRC recommendations [56].

**COVID-19 trial modifications**

As this clinical trial was developed during the COVID-19 pandemic, mitigating approaches were built into the protocol including pre-screening participants over the phone rather than in person and moving all follow-up visits to the participants’ choice of SMS or telephone contact to minimise potential SARS-CoV-2 exposure. As the trial is conducted in a large inner city public hospital it benefits from the hospital’s COVID-19 action plan, including (as indicated) screening of patients before entering a facility, temperature checks and the provision of personal protective equipment to all patients, clinicians and research staff. If the project is significantly impacted by COVID-19 (e.g. a major new outbreak) it will be the responsibility of the Principal Investigator to make any important modifications to the protocol as required to ensure participant safety, and to report according to new CONSORT and SPIRIT Extension for RCTs Revised in Extenuating Circumstances (CONSERVE) guidelines on the reporting of trials impacted by COVID-19 [57].
Ethics and dissemination

This protocol (Version 3.0 dated 01 March 2021) was first approved by the St. Vincent’s Hospital Sydney Human Research Ethics Committee on 22 October 2020 (HREC approval no. 2020/ETH0683) and was prospectively registered with the Australia New Zealand Clinical Trials Registry (registration no. ACTRN12621000045819). Prior to participation, individuals are fully informed about the research and given the opportunity to enquire about details and decide whether or not to participate. If they agree to participate, they are asked to sign the consent form. A copy of the signed consent form is given to each participant. To ensure anonymity and to limit disclosure, participants are assigned a unique identifier at the time of enrolment. Results arising from the main study will be published in peer-reviewed journals and disseminated at international conferences. Results will be reported in such a manner that participants will not be identifiable.

Discussion

To our knowledge this is the first trial of LDX for the treatment of MA withdrawal. Withdrawal is often the first stage of treatment for MAUD. Poorly managed symptoms of withdrawal may be a significant barrier to attaining treatment goals. LDX assisted withdrawal has the potential to improve treatment outcomes through mediating craving [39, 58, 59]. There is currently a paucity of research into treatments for MA withdrawal [10], with multiple sources noting that high quality research is urgently needed [15, 60, 61]. This study follows a novel approach to the management of acute stimulant withdrawal, similar to the management of opioid withdrawal with buprenorphine, which has proven effective in the past [21].

Limitations of this study include the lack of comparison group and small sample size; however, as this is the first time this medication has been used for this indication a single-arm unblinded pilot study approach is appropriate.

Although not designed to detect efficacy, there are significant strengths to this study. The proposed tapering dose regimen may permit withdrawal symptoms and intensity of craving to be modulated over the acute withdrawal period, potentially assisting people to remain in withdrawal treatment for the duration of their care, providing more time for treatment planning and motivational enhancement. This study proposes a novel approach of commencing with a high dose stimulant more closely aligned with what would be consumed extra-medically by this population. Thus, we aim to reduce the risk of a Type-1 error due to under-dosing. Participants are closely monitored throughout the study period by specialist medical staff which will allow for high resolution safety data. This is further strengthened with a follow-up schedule to three weeks post discharge. The study protocol proposes medication delivery in a closely monitored inpatient withdrawal unit to accurately and safely document AEs, which is important as this medication has not been used in this context previously. Further, the proposed intervention is an add-on to usual care (the participants are not admitted expressly to be enrolled in the trial) increasing generalisability in real-world situations and enhancing relevance in other settings such as residential and outpatient services. Results from this study will provide valuable data for a planned RCT investigating the efficacy of LDX to treat MA withdrawal.

Supporting information

S1 File. SPIRIT checklist.
(DOC)

S2 File. Protocol approved by the ethics committee.
(PDF)
Author Contributions
Conceptualization: Liam S. Acheson, Nadine Ezard, Nicholas Lintzeris, Adrian Dunlop, Rebecca McKetin, Krista J. Siefried.
Methodology: Liam S. Acheson, Nadine Ezard, Nicholas Lintzeris, Adrian Dunlop, Jonathan Brett, Craig Rodgers, Anthony Gill, Michael Christmass, Rebecca McKetin, Michael Farrell, Steve Shoptaw, Krista J. Siefried.
Project administration: Liam S. Acheson, Nadine Ezard, Krista J. Siefried.
Supervision: Nadine Ezard, Rebecca McKetin, Michael Farrell, Krista J. Siefried.
Writing – original draft: Liam S. Acheson.
Writing – review & editing: Liam S. Acheson, Nadine Ezard, Nicholas Lintzeris, Adrian Dunlop, Jonathan Brett, Craig Rodgers, Anthony Gill, Michael Christmass, Rebecca McKetin, Michael Farrell, Steve Shoptaw, Krista J. Siefried.

References
1. McKetin R, McLaren J, Kelly E, McKetin R. The Sydney methamphetamine market: Patterns of supply, use, personal harms and social consequences: National Drug Law Enforcement Research Fund; 2005.
2. United Nations. World Drug Report. 2019. Contract No.: E.19.XI.9.
3. Farrell M, Martin NK, Stockings E, Börquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: challenges and opportunities. Lancet. 2019; 394(10209):1652–67. https://doi.org/10.1016/S0140-6736(19)32230-5 PMID: 31668409
4. Hando J, Topp L, Hall W. Amphetamine-related harms and treatment preferences of regular amphetamine users in Sydney, Australia. Drug Alcohol Depend. 1997; 46(1):105–13. https://doi.org/10.1016/s0376-8716(97)00051-3 PMID: 9246558
5. Kaye S, Darke S. A comparison of the harms associated with the injection of heroin and amphetamines. Drug Alcohol Depend. 2000; 58(1):189–95. https://doi.org/10.1016/s0376-8716(99)00102-7 PMID: 10689071
6. Kaye S, McKetin R, Duflou J, Darke S. Methamphetamine and cardiovascular pathology: a review of the evidence. Addiction. 2007; 102(8):1204–11. https://doi.org/10.1111/j.1360-0443.2007.01874.x PMID: 17565661
7. Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017; 390(10100):1211–59. https://doi.org/10.1016/S0140-6736(17)32154-2 PMID: 28919117
8. McGregor C, Srisurapanont M, Jittiwutikarn J, Laoblripatr S, Wongtan T, White JM. The nature, time course and severity of methamphetamine withdrawal. Addiction. 2005; 100(1):1320–9. https://doi.org/10.1111/j.1360-0443.2005.01160.x PMID: 16128721
9. Newton TF, Kalechstein AD, Duran S, Vansliuks N, Ling W. Methamphetamine abstinence syndrome: preliminary findings. Am J Addict. 2004; 13(3):248–55. https://doi.org/10.1080/10550490490459915 PMID: 15370944
10. Shoptaw SJ, Kao U, Heinzeltering K, Ling W. Treatment for amphetamine withdrawal. Cochrane. 2009; (2) https://doi.org/10.1002/14651858.CD003021.pub2 PMID: 19370579
11. Diagnostic and statistical manual of mental disorders: DSM-5. Fifth edition. ed. Arlington, VA: American Psychiatric Publishing; 2013.
12. Ford LK, Zarate P. Closing the gaps: the impact of inpatient detoxification and continuity of care on client outcomes. J Psychoact Drug. 2010; 42(sup6):303–14. https://doi.org/10.1080/029791072.2010.10400554 PMID: 21138207
13. Lee MT, Horgan CM, Garnick DW, Acevedo A, Panas L, Ritter GA, et al. A performance measure for continuity of care after detoxification: Relationship with outcomes. J Subst Abuse Treat. 2014; 47 (2):130–9. https://doi.org/10.1016/j.jsat.2014.04.002 PMID: 24912862
14. Bresliver M, Heinziterling KG, Swanson AN, Shoptaw SJ. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence. Exp Clin Psychopharmacol. 2012; 20(5):430–5. https://doi.org/10.1037/a0029210 PMID: 22867036
15. HärteI-Petri R, Krampe-Scheider A, Braunwarth W-D, Havemann-Reinecke U, Jeschke P, Looser W, et al. Evidence-based guidelines for the pharmacologic management of methamphetamine dependence, relapse prevention, chronic methamphetamine-related, and comorbid psychiatric disorders in post-acute settings. Pharmacopsychiatry. 2017; 50(03):96-104.

16. Meredith CW, Jaffe C, Ang-Lee K, Saxon AJ. Implications of chronic methamphetamine use: a literature review. Harv Rev Psychiatry. 2005; 13(3):141–54. https://doi.org/10.1080/106732205910036605 PMID: 16020027

17. Cruickshank CC, Dyer KR. A review of the clinical pharmacology of methamphetamine. Addiction. 2009; 104(7):1085–99. https://doi.org/10.1111/j.1600-0447.2009.01985.x PMID: 19426298

18. Sekine Y, Ouchi Y, Takei N, Yoshikawa E, Nakamura K, Futatsubashi M, et al. Brain serotonin transporter density and aggression in abstinent methamphetamine abusers. Arc Gen Psychiatry. 2006; 63(1):90–100. https://doi.org/10.1001/archpsyc.63.1.90 PMID: 16389202

19. Volkow ND, Chang L, Wang G-J, Fowler JS, Franceschi D, Sedler M, et al. Loss of dopamine transporter in methamphetamine abusers recovers with protracted abstinence. J Neurosci. 2001; 21(23):9414–8. https://doi.org/10.1523/JNEUROSCI.21-23-09414.2001 PMID: 11717374

20. Bamford NS, Zhang H, Joyce JA, Scarsil CA, Hanan W, Wu N-P, et al. Repeated exposure to methamphetamine causes long-lasting presynaptic cortical striatal depression that is renormalized with drug readministration. Neuron. 2008; 58(1):89–103. https://doi.org/10.1016/j.neuron.2008.01.033 PMID: 18400166

21. Gowling L, Ali R, White JM, Mbewee D. Buprenorphine for managing opioid withdrawal. Cochrane. 2017. (2). https://doi.org/10.1002/14651858.CD002025.pub5 PMID: 28620474

22. Siefried KJ, Acheson LS, Lintzeris N, Ezard N. Pharmacological treatment of methamphetamine/amphetamine dependence: A systematic review. CNS Drugs. 2020; 34(4):337–65. https://doi.org/10.1007/s40263-020-00711-x PMID: 32185696

23. Ezard N, Clifford B, Dunlop A, Bruno R, Carr A, Liu Z, et al. Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. BJM open. 2021; 11(5):e044696. https://doi.org/10.1136/bmjopen-2020-044696 PMID: 34006547

24. Australian Product Information: Vyvanse® (Lisdexamfetamine dimesilate) 2013 (Updated 2020) [https://www.ebs.tga.gov.au/ebps/picmi/picmirepository.nsf/PICMI?OpenForm&l=Lisdexamfetamine]

25. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010; 6:317. https://doi.org/10.2147/ndt.s9749 PMID: 20628632

26. Krishnan SM, Pennick M, Stark JG. Metabolism, distribution and elimination of lisdexamfetamine dimesylate. Clin Drug Invest. 2008; 28(12):745–55.

27. Krishnan SM, Stark JG. Multiple daily-dose pharmacokinetics of lisdexamfetamine dimesylate in healthy adult volunteers. Cur Med Res Opin. 2008; 24(1):33–40. https://doi.org/10.1185/030079908x242737 PMID: 18021493

28. Ermer J, Halfey MB, Richards C, Lasseter K, Roesch B, Purkayastha J, et al. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Clin Drug Invest. 2013; 33(4):243–54. https://doi.org/10.1007/s40263-013-0073-1 PMID: 23512639

29. Martin P, Dirks B, Gertskl, Walling D, Stevenson A, Corcoran M, et al. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia a randomized, double-blind, placebo-controlled trial of ascending multiple doses. J Clin Psychopharmacol. 2014; 34(6):682–9. https://doi.org/10.1097/JCP.0000000000000205 PMID: 25310201

30. Brecht M-L, von Mayrhauser C, Anglin MD. Predictors of relapse after treatment for methamphetamine use. J Psychoact Drug. 2000; 32(2):211–20. https://doi.org/10.1080/10791072.2000.10400231 PMID: 10908010

31. ShoPaw S, Rawson RA, McCann MJ, Obert JL. The Matrix model of outpatient stimulant abuse treatment: evidence of efficacy. J Addict Dis. 1994; 13(4):129–41. https://doi.org/10.1300/j069v13n04_02 PMID: 7734464

32. Lee N, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008; 27(3):309–17. https://doi.org/10.1080/09595230801919494 PMID: 18368613

33. Chan A-W, Tetazaff JM, Altman DG, Laupacis A, Gatzache PC, Krleza-Jerici K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158(3):200–7. https://doi.org/10.7326/M0003-4819-158-3-20130205-00583 PMID: 23295957

34. Chan A-W, Tetzaff JM, Gatzache PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346. https://doi.org/10.1136/bmj.e7586 PMID: 23303884
35. National Health and Medical Research Council, Australia. U. National Statement on Ethical Conduct in Human Research. 2007 (Updated 2018).

36. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health. 2008; 31(2):180–91. https://doi.org/10.1002/nur.20247 PMID: 18183564

37. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharmaceutical Statistics: J Appl Stat. 2005; 4(4):287–91.

38. Public Assessment Report—Lisdexamfetamine Dimesylate, Medicines & Healthcare Products Regulatory Agency. 2015.

39. Longo M, Wickes W, Smout M, Harrison S, Cahill S, White JM. Randomized controlled trial of dexamphetamine maintenance for the treatment of methamphetamine dependence. Addiction. 2010; 105(1):146–54. https://doi.org/10.1111/j.1360-0443.2009.02717.x PMID: 19839966

40. Galloway GP, Buscemi R, Coyle JR, Flower K, Siegrist JD, Fiske LA, et al. A randomized, placebo-controlled trial of sustained-release dextroamphetamine for treatment of methamphetamine addiction. Clin Pharmacol Ther. 2011; 89(2):276–82. https://doi.org/10.1038/cpt.2010.307 PMID: 21178989

41. National Institute of Allergy and Infectious Diseases Division of AIDS (DAIDS). Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected Version 2.1. [July 2017]. In: United States Department of Health and Human Services. 2018.

42. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962; 10(3):799–812.

43. McKetin R, Lubman DI, Baker AL, Dawe S, Ali RL. Dose-related psychotic symptoms in chronic methamphetamine users: evidence from a prospective longitudinal study. JAMA Psychiatry. 2013; 70(3):319–24. https://doi.org/10.1001/jamapsychiatry.2013.283 PMID: 23930471

44. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry. 2011; 168(12):1266–77. https://doi.org/10.1176/appi.ajp.2011.10111704 PMID: 22193671

45. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004; 2(1):12.

46. Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: I. Reliability, validity and factor structure of a measure. Aust NZ J Psychiatry. 1999; 33(1):89–93. https://doi.org/10.1046/j.1440-1614.1999.00517.x PMID: 10197890

47. Lee JW, Brown ES, Perantie DC, Bobadilla L. A comparison of single-item visual analog scales with a multiitem likert-type scale for assessment of cocaine craving in persons with bipolar disorder. Addict Disor Their Treat. 2002; 1(4):140–2.

48. Carney CE, Buysse DJ, Ancoli-Israel S, Edinger JD, Krystal AD, Lichstein KL, et al. The Consensus Sleep Diary: Standardizing Prospective Sleep Self-Monitoring. Sleep. 2012; 35(2):287–302. https://doi.org/10.5665/sleep.1642 PMID: 22294820

49. Ward MF. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993; 150:885- . https://doi.org/10.1176/ajp.150.6.885 PMID: 8494063

50. Gossop M, Darke S, Griffiths P, Hando J, Powis B, Hall W, et al. The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine andamphetamine users. Addiction. 1995; 90(5):607–14. https://doi.org/10.1046/j.1360-0443.1995.9060702.x PMID: 7795497

51. Yiensprugswan V, Seubsman S-a, Khamman S, Lim L-Y, Sleigh AC, Team TCS. Personal wellbeing index in a national cohort of 87,134 Thai adults. Soc Indic Res. 2010; 98(2):201–15. https://doi.org/10.1007/s11205-009-9542-6 PMID: 20835292

52. Mitchell PH, Powell L, Blumenthal J, Norton J, Ironson G, Pittula CR, et al. A short social support measure for patients recovering from myocardial infarction: the ENRICHD Social Support Inventory. J Cardiopulm Rehabil Prev. 2003; 23(6):398–403.

53. Payment of participants in research: information for researchers, HRECs and other ethics review bodies. Canberra, Australia: National Health and Medical Research Council, Australian Research Council and Universities Australia.; 2019.

54. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: Building an international community of software platform partners. J Biomed Inform. 2019; 95:103208. https://doi.org/10.1016/j.jbi.2019.103208 PMID: 31078660

55. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—A metadata-driven methodology and workflow process for providing translational research
56. National Health and Medical Research Council. Data Safety Monitoring Boards. 2018.
57. Orkin AM, Gill PJ, Ghersi D, Campbell L, Sugarman J, Emsley R, et al. Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: The CONSERVE 2021 Statement. JAMA. 2021. https://doi.org/10.1001/jama.2021.9941 PMID: 34152382
58. Hartz DT, Frederick-Osborne SL, Galloway GP. Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend. 2001; 63(3):269–76. https://doi.org/10.1016/s0376-8716(00)00217-9 PMID: 11418231
59. Galloway GP, Singleton EG, Authors MTPC. How long does craving predict use of methamphetamine? Assessment of use one to seven weeks after the assessment of craving. Subst Abuse Res Treat. 2008; 1:SART. S775.
60. Pennay AE, Lee NK. Putting the call out for more research: the poor evidence base for treating methamphetamine withdrawal. Drug Alcohol Rev. 2011; 30(2):216–22. https://doi.org/10.1111/j.1465-3362.2010.00240.x PMID: 21355922
61. Hellem TL. A Review of Methamphetamine Dependence and Withdrawal Treatment: A Focus on Anxiety Outcomes. J Subst Abuse Treat. 2016; 71:16–22. https://doi.org/10.1016/j.jsat.2016.08.011 PMID: 27776672